Cost-effectiveness Analysis of Colorectal Cancer Screening with Stool DNA Testing in Intermediate-incidence Countries

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2006 May 26

PMID 16723013

Citations 21

Authors

Grace Hui-Min Wu

Yi-Ming Wang

Amy Ming-Fang Yen

Jau-Min Wong

Hsin-Chih Lai

Jane Warwick

Tony Hsiu-Hsi Chen

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study is to compare the cost-effectiveness of screening with stool DNA testing with that of screening with other tools (annual fecal occult blood testing, flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years) or not screening at all.

Methods: We developed a Markov model to evaluate the above screening strategies in the general population 50 to 75 years of age in Taiwan. Sensitivity analyses were performed to assess the influence of various parameters on the cost-effectiveness of screening. A third-party payer perspective was adopted and the cost of dollar 13,000 per life-year saved (which is roughly the per capita GNP of Taiwan in 2003) was chosen as the ceiling ratio for assessing whether the program is cost-effective.

Results: Stool DNA testing every three, five, and ten years can reduce colorectal cancer mortality by 22%, 15%, and 9%, respectively. The associated incremental costs were dollar 9,794, dollar 9,335, and dollar 7,717, per life-year saved when compared with no screening. Stool DNA testing strategies were the least cost-effective with the cost per stool DNA test, referral rate with diagnostic colonoscopy, prevalence of large adenoma, and discount rate being the most influential parameters.

Conclusion: In countries with a low or intermediate incidence of colorectal cancer, stool DNA testing is less cost-effective than the other currently recommended strategies for population-based screening, particularly targeting at asymptomatic subjects.

Citing Articles

Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer.

Partyka O, Pajewska M, Czerw A, Deptala A, Mekal D, Sygit K Cancers (Basel). 2025; 17(3).

PMID: 39941735 PMC: 11816288. DOI: 10.3390/cancers17030367.

Health Economic Evaluations of Circulating Tumor DNA Testing for Cancer Screening: Systematic Review.

Rui M, Wang Y, You J Cancer Med. 2025; 14(3):e70641.

PMID: 39907177 PMC: 11795416. DOI: 10.1002/cam4.70641.

Cost-effectiveness analysis of a community-based colorectal cancer screening program in Shanghai, China.

Jiang H, Zhang P, Gu K, Gong Y, Peng P, Shi Y Front Public Health. 2022; 10:986728.

PMID: 36276354 PMC: 9586014. DOI: 10.3389/fpubh.2022.986728.

Characterization and Valuation of the Uncertainty of Calibrated Parameters in Microsimulation Decision Models.

Alarid-Escudero F, Knudsen A, Ozik J, Collier N, M Kuntz K Front Physiol. 2022; 13:780917.

PMID: 35615677 PMC: 9124835. DOI: 10.3389/fphys.2022.780917.

Modelling the impacts of COVID-19 pandemic on the quality of population-based colorectal cancer screening.

Jen G, Yen A, Hsu C, Chiu H, Chen S, Chen T Prev Med. 2021; 151:106597.

PMID: 34217416 PMC: 8241682. DOI: 10.1016/j.ypmed.2021.106597.

References

Dong S, Traverso G, JOHNSON C, Geng L, Favis R, Boynton K . Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001; 93(11):858-65. DOI: 10.1093/jnci/93.11.858. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz Jr D . Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 2002; 346(5):311-20. DOI: 10.1056/NEJMoa012294. View

Koshiji M, Yonekura Y, Saito T, Yoshioka K . Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol. 2002; 80(1):34-40. DOI: 10.1002/jso.10096. View

Pignone M, Saha S, Hoerger T, Mandelblatt J . Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137(2):96-104. DOI: 10.7326/0003-4819-137-2-200207160-00007. View

Blom J, Liden A, Jeppsson B, Holmberg L, Pahlman L . Compliance and findings in a Swedish population screened for colorectal cancer with sigmoidoscopy. Eur J Surg Oncol. 2002; 28(8):827-31. DOI: 10.1053/ejso.2002.1282. View

Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J . Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003; 124(2):544-60. DOI: 10.1053/gast.2003.50044. View

Tagore K, Lawson M, Yucaitis J, Gage R, Orr T, Shuber A . Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer. 2003; 3(1):47-53. DOI: 10.3816/CCC.2003.n.011. View

Rudy D, Zdon M . Update on colorectal cancer. Am Fam Physician. 2000; 61(6):1759-70, 1773-4. View

10.

Chen T, Kuo H, Yen M, Lai M, Tabar L, Duffy S . Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000; 56(1):167-72. DOI: 10.1111/j.0006-341x.2000.00167.x. View

11.

Sonnenberg A, Delco F, Inadomi J . Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med. 2000; 133(8):573-84. DOI: 10.7326/0003-4819-133-8-200010170-00007. View

12.

Ahlquist D, Skoletsky J, Boynton K, Harrington J, Mahoney D, Pierceall W . Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000; 119(5):1219-27. DOI: 10.1053/gast.2000.19580. View

13.

Jouve J, Remontet L, Dancourt V, Lejeune C, Benhamiche A, Faivre J . Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer. 2001; 84(11):1477-81. PMC: 2363664. DOI: 10.1054/bjoc.2001.1752. View

14.

Leshno M, Halpern Z, Arber N . Cost-effectiveness of colorectal cancer screening in the average risk population. Health Care Manag Sci. 2003; 6(3):165-74. DOI: 10.1023/a:1024488007043. View

15.

Song K, Fendrick A, Ladabaum U . Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004; 126(5):1270-9. DOI: 10.1053/j.gastro.2004.02.016. View

16.

Faivre J, Dancourt V, Lejeune C, Tazi M, Lamour J, Gerard D . Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004; 126(7):1674-80. DOI: 10.1053/j.gastro.2004.02.018. View

17.

OConnell J, Maggard M, Ko C . Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96(19):1420-5. DOI: 10.1093/jnci/djh275. View

18.

Stryker S, Wolff B, CULP C, Libbe S, Ilstrup D, MacCarty R . Natural history of untreated colonic polyps. Gastroenterology. 1987; 93(5):1009-13. DOI: 10.1016/0016-5085(87)90563-4. View

19.

Achkar E, Carey W . Small polyps found during fiberoptic sigmoidoscopy in asymptomatic patients. Ann Intern Med. 1988; 109(11):880-3. DOI: 10.7326/0003-4819-109-11-880. View

20.

Hixson L, Fennerty M, Sampliner R, Garewal H . Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps. Gastrointest Endosc. 1991; 37(2):125-7. DOI: 10.1016/s0016-5107(91)70668-8. View